FcgammaRIIa-H ADCP Reporter Bioassay, Core Kit
Antibody-dependent cell-mediated phagocytosis (ADCP) is an important mechanism of action (MOA) of therapeutic antibodies. In vivo, ADCP can be mediated by monocytes, macrophages, neutrophils and dendritic cells via FcgammaRIIa, FcgammaRI and FcgammaRIIIa. While all three receptors can participate in ADCP, FcgammaRIIa is believed to be the predominant Fcgamma receptor involved in this process. The FcgammaRIIa-H ADCP Reporter Bioassay is a biologically relevant MOA-based assay that can be used to measure the potency and stability of antibodies and other biologics that specifically bind and activate FcgammaRIIa. The assay consists of Jurkat cells stably expressing human FcgammaRIIa-H (the high-affinity H131 variant) and NFAT-induced luciferase. The bioassay is prequalified according to ICH guidelines and shows the precision, accuracy and linearity required for routine use in potency and stability studies. The bioassay workflow is simple and robust, compatible with 96-well and 384-well plate formats, and unlike traditional primary cell-based assays, amenable for use in quality-controlled drug development settings. The FcgammaRIIa-H ADCP Reporter Bioassay is available in multiple product kit formats: Complete Kit includes FcgammaRIIa-H Effector Cells, Target Cells (Raji), Control Antibody, Cell Culture Medium and Assay Reagents and is recommended for use as a starter kit. Core Kits include FcgammaRIIa-H Effector Cells, Cell Culture Medium and Assay Reagents; are recommended for routine use with customer-defined antibody and target cells; and are available in 1X and 5X sizes.